Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15128284 | 0.80 | KDM4E (0.35) | KDM4EALDH1A1POLBHPGDHSD17B10 | |
| SCHEMBL15128277 | 0.80 | — | — | |
| SCHEMBL15128265 | 0.77 | — | — | |
| SCHEMBL15128251 | 0.72 | — | — | |
| SCHEMBL13677554 | 0.69 | KDM4E (0.34) | KDM4EALDH1A1HPGD | |
| SCHEMBL12999247 | 0.68 | — | — | |
| SCHEMBL14536340 | 0.66 | — | — | |
| SCHEMBL7936026 | 0.65 | KDM4E (0.43) | KDM4EALDH1A1POLBHPGDHSD17B10 | |
| SCHEMBL5056754 | 0.65 | — | — | |
| SCHEMBL8523180 | 0.64 | KDM4E (0.31) | KDM4EALDH1A1POLBHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4289813-A2 | INTERMEDIATES TO OBTAIN SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | Global Blood Therapeutics, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-3738434-A1 | INTERMEDIATES TO OBTAIN SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | Global Blood Therapeutics, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| EP-3192789-A1 | NITROGENATED HETEROCYCLIC RING DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME | Idemitsu Kosan Co., Ltd. (JP) | 2017-07-19 | — | — | EP | disclosed |
| US-20120149699-A1 | IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149699-A1 | IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS | TRPM8, TRPV1, TRPM2 | KDM4E 3480/4885ALDH1A1 2230/4885POLB 4591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.